Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study
2021 · European Journal of Cancer · 70 citations
https://doi.org/10.1016/j.ejca.2021.01.005
D
Denis Maillet
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
121
Papers
2.9K
Citations
26
h-index
40
i10-index
Denis Maillet is an academic researcher from Hospices Civils de Lyon. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Renal cell carcinoma treatment & Bladder and Urothelial Cancer Treatments. The author has an h-index of 26, co-authored 103 publications.
ORCID: 0000-0001-6883-2696Papers by this author
worksComplete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients’ Outcomes?
2023 · Cancers · 18 citations
https://doi.org/10.3390/cancers15030793
Synergistic effect between denosumab and immune checkpoint inhibitors (ICI)? A retrospective study of 268 patients with ICI and bone metastases
2024 · Journal of bone oncology · 6 citations
https://doi.org/10.1016/j.jbo.2024.100634
Evolving Practices in Immune-Related Adverse Event Management: Insights From the IMMUCARE Multidisciplinary Board
2024 · JCO Oncology Practice · 5 citations
https://doi.org/10.1200/op.24.00042
Real-World Evaluation of ImmuCare Patient-Reported Outcomes in Melanoma Patients Treated with Immune-Checkpoint Inhibitors
2024 · EJC Skin Cancer · 0 citations
https://doi.org/10.1016/j.ejcskn.2024.100164
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat